<DOC>
	<DOCNO>NCT00134030</DOCNO>
	<brief_summary>This randomized phase III trial study combination chemotherapy follow surgery two different combination chemotherapy regimens without PEG-interferon alfa-2b compare well work treat patient osteosarcoma . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Biological therapy , PEG-interferon alfa-2b , may interfere growth tumor cell . Giving combination chemotherapy surgery may shrink tumor remove . Giving combination chemotherapy together PEG-interferon alfa-2b surgery may kill remain tumor cell . It yet know whether give combination therapy together PEG-interferon alfa-2b effective two different combination chemotherapy regimens alone surgery treat osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy , PEG-Interferon Alfa-2b , Surgery Treating Patients With Osteosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare whether adjuvant maintenance therapy comprise doxorubicin , cisplatin , high-dose methotrexate ( MAP ) alone vs MAP combine ifosfamide etoposide improve event-free survival patient resectable high-grade osteosarcoma achieve poor histological response ( HR ) neoadjuvant induction therapy comprise MAP . II . Compare whether adjuvant maintenance therapy comprise MAP alone vs MAP PEG-interferon alfa-2b improves event-free survival patient resectable high-grade osteosarcoma achieve good HR neoadjuvant induction therapy comprise MAP . SECONDARY OBJECTIVES : I . Compare overall survival patient treat regimen . II . Compare short- long-term toxicity regimens patient . III . Compare quality life patient treat regimen . IV . Compare event-free survival overall survival patient localize osteosarcoma treat regimen . V. Correlate biological clinical change histological response outcomes patient treat regimen . VI . Determine outcomes patient treat regimen . OUTLINE : This randomize , control , multicenter study . INDUCTION THERAPY : ( MAP ; week 1-10 ) Patients receive doxorubicin IV continuously 48 hour day 1-2 cisplatin IV 4 hour day 1 2 week 1 6 . Patients also receive high-dose methotrexate ( MTX ) * IV 4 hour day 1 week 4 , 5 , 9 , 10 . Patients proceed surgery . NOTE : *Patients must receive &gt; = 2 = &lt; 6 dos high-dose MTX . SURGERY : Patients undergo amputation limb salvage surgery week 11 . Tumor tissue evaluate histological response induction therapy . Patients whose tumor amenable macroscopically complete surgical resection undergo radiotherapy and/or investigational therapy study . Patients undergo macroscopically complete surgical resection primary tumor metastasis AND disease progression unacceptable toxicity proceed maintenance therapy . MAINTENANCE THERAPY : Patients assign 1 2 group accord histological response ( good [ &lt; 10 % viable tumor ] v poor [ ≥ 10 % viable tumor ] ) . Patients group stratify accord site primary tumor presence metastasis . GROUP 1 : ( good histological response ) Patient randomize 1 2 treatment arm within 35 day surgery . ARM I : ( MAP ; week 12-29 ) Patients receive doxorubicin IV continuously 48 hour day 1-2 week 12 , 17 , 22 , 26 cisplatin IV 4 hour day 1 2 week 12 17 . Patients also receive high-dose MTX IV 4 hour day 1 week 15 , 16 , 20 , 21 , 24 , 25 , 28 , 29 . ARM II : ( MAPifn ; week 12-104 ) Patients receive doxorubicin , cisplatin , high-dose MTX arm I . Patients receive PEG-interferon alfa-2b subcutaneously daily day 1 week 30-104 . GROUP 2 : ( poor histological response ) Patients randomize 1 2 treatment arm within 35 day surgery . ARM I : ( MAP ; week 12-29 ) Patients receive doxorubicin , cisplatin , high-dose MTX group 1 arm I . ARM II : ( MAPIE ; week 12-40 ) Patients receive doxorubicin IV continuously 48 hour day 1-2 week 12 , 20 , 28 , 36 cisplatin IV 4 hour day 1 2 week 12 28 . Patients also receive high-dose MTX IV 4 hour day 1 week 15 , 19 , 23 , 27 , 31 , 35 , 39 , 40 . Patients receive ifosfamide IV 4 hour day 1-5 week 16 , 24 , 32 day 1-3 week 20 36 etoposide IV 1 hour day 1-5 week 16 , 24 , 32 . In group , treatment continue absence disease progression unacceptable toxicity . Quality life assess periodically . After completion study treatment , patient follow every 1½-3 month 2 year , every 2-4 month 2 year , every 6 month 6 year , every 6-12 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Histologically confirm highgrade osteosarcoma , include second malignancy Localized metastatic disease The primary tumor must locate limbs axial skeleton , include follow sites* : Long bone upper limb Short bone upper limb Long bone low limb Short bone low limb Vertebral column Ribs , sternum , clavicle , scapula Pelvic bone , sacrum , coccyx Tumor ( primary , metastatic , ) resectable OR expect become resectable neoadjuvant induction chemotherapy Suitable neoadjuvant chemotherapy Performance status Lansky 50100 % ( patient 16 year age ) Performance status Karnofsky 50100 % * Performance status WHO ECOG 02* Platelet count ≥ 100,000/mm³ Neutrophil count ≥ 1,500/mm³ WBC ≥ 3,000/mm³ Bilirubin ≤ 1.5 time upper limit normal Creatinine clearance ≥ 70 mL/min Creatinine base age follow : No great 1.0 mg/dL ( patient 5 10 year age ) No great 1.2 mg/dL ( patient 11 15 year age ) No great 1.5 mg/dL ( patient 15 year age ) Ejection fraction ≥ 50 % radionuclide angiogram Shortening fraction ≥ 28 % echocardiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No prior chemotherapy disease Prior radiotherapy another malignancy allow No prior treatment osteosarcoma</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>